DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Tuesday

DiaMedica Therapeutics (NASDAQ:DMAC) is expected to be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 13th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.18) per share for the quarter.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Up 1.9%

DMAC stock opened at $3.76 on Monday. The company has a market cap of $161.14 million, a price-to-earnings ratio of -6.71 and a beta of 1.29. The business has a fifty day simple moving average of $4.31 and a 200-day simple moving average of $5.01. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price objective on DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, March 19th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.